Janssen and Legend Biotech Joining Forces to Advance Myeloma CAR T-cell Therapy
Janssen Biotech and China’s Legend Biotech are teaming up to continue developing and to market Legend’s CAR T-cell therapy for multiple myeloma. A hot…
News
BioLineRx Readies Phase 3 Myeloma Trial to Mobilize Stem Cells for Transplant
BioLineRx has launched a Phase 3 trial to assess if adding BL-8040 to standard treatment will improve the outflux of blood stem cells from…
Biomarker Found That Detects Myeloma Patients Who Will Benefit from Stem Cell Transplant
A collaboration between GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) resulted in the discovery of a biomarker called CHEK1 that detects which…
CellProtect Receives EU Orphan Drug Status for Treatment of Multiple Myeloma
The European Commission has granted orphan drug status to CellProtect as a treatment for multiple myeloma, according to the investigational therapy’s developer, CellProtect…
Adaptimmune Immunotherapy Increases Time It Takes for Myeloma to Progress, Trial Shows
An Adaptimmune therapy that strengthens immune T-cells’ response to cancer has helped patients with advanced myeloma live as long as five years without their disease progressing,…
Weighing Myeloma Cells Could Predict Treatment Responses, MIT Study Shows
Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of Technology study reports. The findings could…
First Myeloma CAR T-cell Therapy Phase 2 Trial Opens Enrollment
The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell therapy for multiple myeloma —…
FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns
The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial…
Ascentage Gets FDA Nod to Advance APG-1387 into Clinical Trials for Myeloma, Other Cancers
The U.S. Food and Drug Administration (FDA) has accepted Ascentage Pharma‘s Investigational New Drug (IND) application for APG-1387, allowing Ascentage to test the…
CAR T-cells Targeting Integrin β7 Protein Show Promise in Countering Multiple Myeloma Cells
A Japanese study has found that an active structure of the protein integrin β7 is specific to multiple myeloma cells, suggesting that it could be…
